AbbVie

AbbVie Inc. is an American multinational biopharmaceutical company focused on discovery, development, and marketing of medicines. It was established in 2013 as a spin-off of Abbott Laboratories and began operating as an independent company on January 1, 2013. The company is headquartered in North Chicago, Illinois, and conducts business in more than 170 countries through a portfolio of prescription medicines and branded therapies.

AbbVie’s portfolio centers on immunology, oncology, neuroscience, and virology, with products marketed globally. Its immunology line has included Humira, one of the world's best-selling drugs for autoimmune diseases. The oncology franchise includes agents such as Imbruvica and Venclexta, developed in collaboration with partners. Since acquiring Allergan in 2019, AbbVie also markets Botox and a range of aesthetic, eye care, and specialty medicines through that business.

AbbVie is publicly traded on the New York Stock Exchange under the ticker ABBV and is a member of major indices including the S&P 500. The company invests heavily in research and development and pursues external collaborations to expand its pipeline. As with many large biopharmaceutical firms, AbbVie faces patent expirations and competition from biosimilars affecting some leading products.